Follicle-stimulating hormone (FSH) is a pituitary gonadotroph-derived heterodimeric glycoprotein that binds G proteincoupled FSH receptors (FSHRs) on ovarian granulosa cells [1] [2] [3] . This FSH/FSHR signaling pathway is essential for female fertility because null mice lacking either the FSH ligand [4] or FSHR [5, 6] are sterile as a result of preantral stage block in ovarian folliculogenesis. These FSH ligand/receptor null mice phenocopy women harboring inactivating mutations (homozygous recessive) in corresponding alleles encoding the hormone-specific FSH beta subunit and FSHR [7, 8] . A number of in vitro and in vivo studies have documented the cascade of signaling events elicited by FSH binding to FSHRs on granulosa cells [2, 3, 9] . Although the predominant signaling pathway activated by FSH is cAMP-mediated phosphorylation of PKA and CREB, activation of other signaling pathways, including the mitogen-activated protein kinase pathway, has also been identified [8, 10] . Interestingly, several FSHR isoforms are expressed in ovary (presumably on granulosa cells of preantral follicles) prior to the well-known FSH actions during early folliculogenesis [11] [12] [13] [14] . However, the functional significance of these FSHR isoforms is unknown.
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Although the classical prevailing view is that pituitaryderived FSH acts on ovarian granulosa cells in the female, emerging evidence suggests FSH may exert physiological effects on extragonadal tissues and organs as well. A series of studies document that FSH acts on osteoclasts by activating FSHRs via a nonclassical pathway and regulates bone mass in mice [15] [16] [17] [18] [19] . Consistent with this, women carrying a polymorphism in FSHR resulting in hyperactivation of FSHRs are more prone to bone loss [20] . However, FSH actions on bone osteoclasts remain controversial [21, 22] . Moreover, FSH actions on monocytes [23, 24] and human umbilical vein endothelial cells [25] and expression of FSHRs on endothelial cells of the tumor vasculature [26] have been reported. In a recent issue of Biology of Reproduction (BOR), Stilley and colleagues present their remarkable findings on FSHR expression in the human female reproductive tract and developing placenta and feto-placental defects in an Fshr mutant mouse model [27] .
FSHR Expression in Human Placenta
An essential reagent required to confirm extragonadal and placental FSHR expression is a specific antibody thoroughly validated because the cell surface expression of a given Gprotein coupled receptor (GPCR) on a primary target tissue itself is very low. In the present studies, Stilley and colleagues used two well-characterized antibodies [27] . One was a mouse monoclonal antibody (mAB) developed by Milgrom and colleagues that specifically recognized the extracellular domain of the human FSHR [28] . The second was a rabbit anti-rat FSHR polyclonal antibody developed by the Ascoli group that did cross-react with the mouse FSHR [29] . Although previous studies validated the mAB [25, 28] , Stilley and colleagues [27] established that the mAB was FSHR specific by assessing the lack of cross-reactivity with closely related luteinizing hormone receptors (LHRs). Using this mAB, a series of high-quality images representing the immunochemical localization of FSHRs in the human placenta (obtained at different gestation periods) were generated.
In the first set of experiments, Stilley and colleagues tested FSHR expression in placentae between 38 and 40 wk of gestation. They found intense FSHR staining in endothelial cells of blood vessels in chorionic villi, a weak staining in these villi stromal cells [27] , and, interestingly, no staining in trophoblasts that produce chorionic gonadotropin subunits. Additionally, FSHRs were expressed in the epithelial cells of the outer layer of the amnion and stromal fibroblasts. Prominent staining was observed in clustered subsets of maternal decidua, endothelial cells of the maternal blood vessels within the decidua. FSHR expression was also noted in umbilical artery smooth muscle cells, umbilical vein, amniotic epithelium, and fibroblasts within Wharton jelly [27] .
In the second set of experiments, Stilley and colleagues examined FSHR expression in placentae and umbilical cords between 28 and 30 wk of gestation. These analyses revealed a nearly identical FSHR staining pattern to those obtained with term samples [27] . In the third set of experiments they observed similar FSHR staining when samples obtained from 18-20 wk of gestation were tested. Notably, they found nonhomogeneous FSHR expression in maternal decidua, consistent with maternal spiral artery remodeling at this stage of gestation [27] . Finally, in the fourth set of experiments, FSHR protein expression was investigated in placentae and associated tissues at 8-10 wk of gestation. Although FSHR staining was intense in endothelial cells of the developing chorionic villi, it was moderate in stromal cells and no staining was observed in trophoblasts. Compared to the staining in decidua at more advanced stages of gestation, FSHR staining was more intense in decidua at this early stage [27] .
Feto-Placental Defects in Fshr-Null Mice
Stilley and colleagues next examined FSHR expression in term mouse placenta. Their data convincingly demonstrated that FSHRs were expressed in the vasculature of the labyrinth zone of mouse term placenta [27] . FSHR-specific polyclonal antibody staining of placentae associated with Fshr À/À fetuses showed no FSHR expression. Intercrosses between male and female Fshr þ/À mice were subsequently set up and this allowed testing of whether progeny embryos lacking a single or both copies of Fshr showed any feto-placental phenotypes. Stilley and colleagues identified that haplo-insufficiency of fetoplacental Fshr blunted placental growth: Fshr À/À fetuses weighed less than their littermate controls; moreover, they identified midgestation loss of Fshr þ/À and Fshr À/À fetuses [27] .
Extragonadal FSHRs in the Human Female Reproductive Tract
Having extensively characterized the FSHR expression in human placental and uterine tissues during pregnancy, Stilley and colleagues next examined FSHRs in nonovarian tissues of the nonpregnant female reproductive tract. They found FSHRs expressed in nonpregnant endometrium in both proliferative and secretory phases and in cervical glandular epithelium and muscle fibers. Nonpregnant myometrium showed similar FSHR immunostaining results as cervix. Interestingly, FSHR expression was high in endothelial cells, arterial smooth muscle cells and ;10-fold higher in the muscle fibers and stroma of myometrium samples from women at term than those obtained from nonpregnant myometrium [27] . 
KUMAR

Local Production of FSH Subunits in the Human Pregnant Uterus and Nonovarian Tissues
Because maternal pituitary FSH production is suppressed during pregnancy, Stilley and colleagues tested if a local autocrine FSH/FSHR signaling system exists in pregnant uterus and nonreproductive tissues. Low-level expression of CGA and FSHB encoding subunits was detected by PCR in a number of nonovarian tissues including uteroplacental tissue (including the maternal decidua and placenta), placenta (maternal decidua and amnion removed), maternal uterine decidua, and uterine myometrium from term pregnancy. Furthermore, PCR analyses also revealed that full-length, but not the splice variants of, mRNA encoding FSHRs was also expressed in human myometrium [27] .
Summary and Future Directions
Stilley and colleagues previously reported FSHR-mediated signaling on human umbilical vein endothelial cells promotes angiogenesis [25] . In this BOR paper, they extend these findings and provide a thorough characterization of FSHR expression in a variety of extraovarian tissues from nonpregnant and pregnant women (Fig. 1) . These studies, although limited mostly to FSHR expression, were thoroughly done with appropriate controls. Functional significance of these extragonadal FSHRs in feto-placental development was highlighted by their studies with the Fshr mutant mouse model. It should be noted that the nonovarian FSHR expression resembles that of LHCGR expression in nonovarian human tissues as described in pioneering studies conducted by Rao and his colleagues beginning from 1990 [30] [31] [32] [33] . Interestingly, recent genetic studies identified association of SNPs in FSHR gene to preterm birth [34, 35] . Therefore, it is tempting to speculate that defects in signaling via FSHRs in nonovarian tissues could likely contribute to risks for adverse pregnancy outcomes. Long-term multicenter clinical studies must be performed to confirm these genome-wide association studies. In addition, further studies are required to determine the physiological and pathological relevance of FSH/FSHR signaling during human pregnancy.
The studies by Stilley and colleagues [27] have opened numerous avenues for further research. First, mice with an Fshr flox must be developed. These mice should be useful to systematically delete Fshr spatiotemporally in nonovarian tissues using different Cre deleter strains and genetic strategies [36] [37] [38] [39] . The physiological consequences of loss of extragonadal Fshr on embryo implantation and feto-placental development and function could then be assessed in a physiological context. Second, although pregnant myometrium expresses full-length mRNA encoding FSHRs, it remains to be tested which signaling pathway would be activated upon locally produced FSH binding. In vivo consequences of disruption of those signaling pathways could then be explored using the Fshr conditional deletion mouse models described above. Third, women with germ line mutation in FSHR are infertile because of ovarian insufficiency [7, 8] . Clinical studies involving these women willing to serve as recipients for donor egg/embryo transfer could be explored. Such studies would directly test if uterine environment lacking FSHRs in these women supports donor embryos carrying wild-type FSHR [40, 41] . Finally, it would be interesting to delineate the mechanisms that regulate signaling via FSHRs and specifically determine whether cyclic exposure to steroid hormones during each menstrual cycle would modulate FSHR expression in extraovarian tissues in the female. 
